| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.7M | — | -19.8% |
| SG&A Expense | $4.7M | — | -8.9% |
| Operating Income | -$14.5M | — | +16.5% |
| Net Income | -$13.6M | — | +14.0% |
| EPS (Basic) | -$0.60 | — | +15.5% |
| EPS (Diluted) | -$0.60 | — | +15.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $17.5M | -2.2% | +15.7% |
| Short-term Investments | $75.4M | -16.0% | -38.8% |
| Current Assets | $94.6M | -13.7% | -32.6% |
| Total Assets | $141.0M | -10.2% | -26.3% |
| Current Liabilities | $9.6M | -23.6% | +51.2% |
| Total Liabilities | $54.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$15.0M | — | -3.0% |
| Capital Expenditures | $8K | — | -86.4% |
| Investing Cash Flow | $14.6M | — | +376.7% |
| Free Cash Flow | -$15.0M | — | -2.7% |
| -0.1% |
| Stockholders' Equity | $86.4M | -12.4% | -36.8% |